Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1978 May;31(5):488–492. doi: 10.1136/jcp.31.5.488

Coagulation and fibrinolytic activity of cerebrospinal fluid.

M Anderson, K B Matthews, J Stuart
PMCID: PMC1145309  PMID: 649775

Abstract

Fibrin/fibrinogen degradation products (fragments D and E) were detected in cerebrospinal fluid in 23.4% of 252 patients admitted to a neurological/neurosurgical unit. Other coagulation proteins of low molecular weight (plasminogen and factor IX) were also present but larger proteins (fibrinogen and factor V) were not. These findings are consistent with protein leakage across a blood-CSF barrier damaged by inflammatory, vascular, or neoplastic disease. Fibrin/fibrinogen degradation products in cerebrospinal fluid after subarachnoid haemorrhage may not, therefore, be a reliable index of increased fibrinolytic activity in the subarachnoid space and may be misleading when selecting patients for fibrinolytic blockade.

Full text

PDF
488

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASTRUP T., MULLERTZ S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952 Oct;40(2):346–351. doi: 10.1016/0003-9861(52)90121-5. [DOI] [PubMed] [Google Scholar]
  2. Astedt B., Adielsson G., Mattsson W. Fibrin/fibrinogen degradation products in pleural exudate. Lancet. 1976 Aug 21;2(7982):414–414. doi: 10.1016/s0140-6736(76)92424-7. [DOI] [PubMed] [Google Scholar]
  3. Benz J. J. Clotting factors and fibrinogen split products in the extravasular space. Thromb Diath Haemorrh. 1968 Mar 31;19(1):226–235. [PubMed] [Google Scholar]
  4. Brueton M. J., Breeze G. R., Stuart J. Fibrin-fibrinogen degradation products in cerebrospinal fluid. J Clin Pathol. 1976 Apr;29(4):341–344. doi: 10.1136/jcp.29.4.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brueton M. J., Tugwell P., Whittle H. C., Greenwood B. M. Fibrin degradation products in the serum and cerebrospinal fluid of patients with group A meningococcal meningitis. J Clin Pathol. 1974 May;27(5):402–404. doi: 10.1136/jcp.27.5.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cash J. D., Allan A. G. Effect of mental stress on the fibrinolytic reactivity to exercise. Br Med J. 1967 May 27;2(5551):545–548. doi: 10.1136/bmj.2.5551.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clarkson A. R., MacDonald M. K., Petrie J. J., Cash J. D., Robson J. S. Serum and urinary fibrin-fibrinogen degradation products in glomerulonephritis. Br Med J. 1971 Aug;3(5772):447–451. doi: 10.1136/bmj.3.5772.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Donati M. B., Semeraro N., Vermylen J. Detection of fibrinogen antigens with two latex techniques applied to urine concentrates. J Clin Pathol. 1973 Oct;26(10):760–763. doi: 10.1136/jcp.26.10.760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hall C. L., Pejhan N., Terry J. M., Blainey J. D. Urinary fibrin-fibrinogen degradation products in nephrotic syndrome. Br Med J. 1975 Feb 22;1(5955):419–422. doi: 10.1136/bmj.1.5955.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hunter R., Thomson T., Reynolds C. M., Pitcher P. M. Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients admitted to a psychiatric unit. J Neurol Neurosurg Psychiatry. 1974 Mar;37(3):249–251. doi: 10.1136/jnnp.37.3.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. MEULEMANS O. Determination of total protein in spinal fluid with sulphosalicylic acid and trichloroacetic acid. Clin Chim Acta. 1960 Sep;5:757–761. doi: 10.1016/0009-8981(60)90020-6. [DOI] [PubMed] [Google Scholar]
  12. Mullan S., Dawley J. Antifibrinolytic therapy for intracranial aneurysms. J Neurosurg. 1968 Jan;28(1):21–23. doi: 10.3171/jns.1968.28.1.0021. [DOI] [PubMed] [Google Scholar]
  13. NEWMAN R. L., STEWART G. T. THE USE OF FIBRINOLYTIC ACTIVATORS IN MENINGITIS AND SIMILAR CONDITIONS. Arch Dis Child. 1965 Jun;40:235–242. doi: 10.1136/adc.40.211.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Naish P., Evans D. J., Peters D. K. Urinary fibrinogen derivative excretion and intraglomerular fibrin deposition in glomerulonephritis. Br Med J. 1974 Mar 23;1(5907):544–546. doi: 10.1136/bmj.1.5907.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nibbelink D. W., Torner J. C., Henderson W. G. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975 Nov-Dec;6(6):622–629. doi: 10.1161/01.str.6.6.622. [DOI] [PubMed] [Google Scholar]
  16. Pennock C. A., Passant L. P., Bolton F. G. Estimation of cerebrospinal fluid protein. J Clin Pathol. 1968 Jul;21(4):518–520. doi: 10.1136/jcp.21.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ransohoff J., Goodgold A., Benjamin M. V. Preoperative management of patients with ruptured intracranial aneurysms. J Neurosurg. 1972 May;36(5):525–530. doi: 10.3171/jns.1972.36.5.0525. [DOI] [PubMed] [Google Scholar]
  18. STEWART G. T. FIBRINOLYTIC THERAPY IN MENINGITIS AND VENTRICULITIS. J Clin Pathol. 1964 May;17:355–359. doi: 10.1136/jcp.17.3.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schliep G., Felgenhauer K. The alpha2-macroglobulin level in cerebrospinal fluid; a parameter for the condition of the blood-CSF barrier. J Neurol. 1974;207(3):171–181. doi: 10.1007/BF00312558. [DOI] [PubMed] [Google Scholar]
  20. Sengupta R. P., So S. C., Villarejo-Ortega F. J. Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg. 1976 Apr;44(4):479–484. doi: 10.3171/jns.1976.44.4.0479. [DOI] [PubMed] [Google Scholar]
  21. Smith R. R., Upchurch J. J. Monitoring antifibrinolytic therapy in subarachnoid hemorrhage. J Neurosurg. 1973 Mar;38(3):339–344. doi: 10.3171/jns.1973.38.3.0339. [DOI] [PubMed] [Google Scholar]
  22. Svanberg L., Astedt B. Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors. Cancer. 1975 May;35(5):1382–1387. doi: 10.1002/1097-0142(197505)35:5<1382::aid-cncr2820350522>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  23. Tovi D., Nilsson I. M., Thulin C. A. Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand. 1972;48(4):393–402. doi: 10.1111/j.1600-0404.1972.tb07561.x. [DOI] [PubMed] [Google Scholar]
  24. Tovi D., Nilsson I. M., Thulin C. A. Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage. Acta Neurol Scand. 1973;49(1):1–9. doi: 10.1111/j.1600-0404.1973.tb01274.x. [DOI] [PubMed] [Google Scholar]
  25. WOLF P. A modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma. J Clin Pathol. 1953 Feb;6(1):34–38. doi: 10.1136/jcp.6.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Whittle H. C., Greenwood B. M. Cerebrospinal fluid immunoglobulins and complement in meningococcal meningitis. J Clin Pathol. 1977 Aug;30(8):720–722. doi: 10.1136/jcp.30.8.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wu K. K., Jacobsen C. D., Hoak J. C. Plasminogen in normal and abnormal human cerebrospinal fluid. Arch Neurol. 1973 Jan;28(1):64–66. doi: 10.1001/archneur.1973.00490190082012. [DOI] [PubMed] [Google Scholar]
  28. de Vreker R. A. A technique for routine evaluation of plasminogen in humans during streptokinase therapy. Acta Haematol. 1965 Nov;34(5):305–320. doi: 10.1159/000209454. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES